BSL >> Safety Assessment >> Pharmaceuticals

Non-clinical Toxicology Testing

BSL BIOSERVICE performs toxicology studies in close cooperation with its partner Eurofins BioPharma Product Testing Munich and has successfully established a wide range of in vivo and in vitro study designs to evaluate the safety of your drug candidates.

in vivo Studies
Over the past 30 years BSL BIOSERVICE gained a wide range of experience in acute, subchronic and chronic toxicity studies using various routes of administration in small and large animals, which are housed in state-of-the-art facilities with highest quality standards. We provide extensive knowledge in the testing of a variety of drug compounds in all relevant species.

in vitro Studies
Eurofins BioPharma Product Testing Munich GmbH has offered over the past a broad scope of in vitro tests, resulting in an extensive pool of historical data. Test systems are conducted under GLP compliance and meet the regulatory requirements for the safety testing of new drugs. For your early drug candidates we are well prepared to approach the safety assessment by applying economic screening protocols.

Complete IND Packages
BSL BIOSERVICE and Eurofins BioPharma Product Testing Munich provide full nonclinical development programs in support of IND and later-stage regulatory submissions for new chemical (NCE) or biological entities (NBE). On the basis of more than 20 years of experience we are guiding your project with highest flexibility and efficiency to IND and beyond.

Comprehensive Toxicology Studies

  • Cytotoxicity, Phototoxicity in vitro
  • Acute Toxicity
  • Subacute, Subchronic, Chronic Toxicity
  • Carcinogenicity
  • Developmental & Reprodutive Toxicity (DART)
  • Sensitization
  • Local Tolerance Studies
    (single or repeated applications)
  • Genetic Toxicology
  • Safety Pharmacology
  • Immunotoxicity
  • Immunogenicity
  • Bioanalytics
  • in vitro Dermal Sensitization, Absorption & Toxicology

Alternative Toxicology Testing Services
Eurofins BioPharma Product Testing Munich is also offering methods for replacing the use of animals to evaluate acute systemic toxicity, skin and eye irritation and skin allergenicity but also reduce the use of animals for repeated-dose toxicity, carcinogenicity and reproductive toxicity.